Neurology Central

World Multiple Sclerosis Day – a note from the Editor

0
Today (30 May) marks World Multiple Sclerosis (MS) Day: an annual opportunity to raise awareness of MS and to work together as a global community to find ways to improve the lives of those with MS. We wanted to use this opportunity to mark some of the recent research and developments in the field over the course of the year so far.

This year’s theme for the international campaign is #BringingUsCloser – you can find out more about how MS research is bringing us closer to ending MS by following the hashtag on Twitter:

The year so far in MS research

Stem cell trial

Our most read article in the field so far features, ‘Stem cell transplant could be ‘game changer’ for MS patients’. Where earlier last month, an international trial (MIST) revealed that hematopoietic stem cell transplantation was an effective and safe treatment option for patients with relapsing MS. The researchers concluded that hematopoietic stem cell transplantation was statistically superior to continued disease-modifying therapies in patients with relapsing–remitting MS with ≥2 relapses a year.

Industry breakthroughs

We’ve also seen a large number of industry news being featured around MS, with an announcement in March that siponimod could improve outcome in patients with secondary progressive MS. Almost 1 month later, results from the EXPAND study of oral siponimod were announced, revealing that Novartis was filing for regulatory approval with the US FDA. Furthermore, towards the end of April, additional Phase III data for siponimod were announced once again.

The highlights above are only a select few of all the fantastic research that has happened so far in the research field – we’ve also compiled all our exclusive content on MS in the year so far, below:

Further headlines from 2018

News articles:

Interviews:

Future project on multiple sclerosis

Finally, we’re delighted to announce a future project that we’re currently working on, entitled: ‘Ask the Experts: emerging therapies in multiple sclerosis’. We’re hoping to get this feature published in June for you, so be sure to stay tuned to Neuro Central to find out more about this.

We hope that you’ve enjoyed our selection of content from the year so far. We’re very much looking forward to continuing to bring updates from across the field to those researching, living with and fighting MS.

My very best wishes,
Sharon Salt
Editor, Neuro Central

Like what you see? Become a member FREE of charge for full access to all features, as well as complimentary access to our five partnered journals: Future Neurology, Neurodegenerative Disease Management, Pain Management, CNS Oncology and the open access journal Concussion.

Share:

Leave A Comment